I should have phrased it "the one patient from the abstract in the 11th" is 4 months from the first treatment. If he had partial or complete response we would have known by now given Leo had to PR something to stop the bleeding from the SA hack job. His "update" on trial progress would have most certainly included that.
Maybe - just opinion - they expanded cohort 11 at the 750 mark if they are seeing another 1 or 2 tumor types that are starting to respond in a manner like the ovarian cancer tumors given ORPHAN DRUG designation. If so, probably make sense to check this or these tumor type(s) at 750 with expanded patients, before going to an increased dosage where a risk of a DLT might (who knows when) occur.
Market Data 
Markets 
AI
